Action BIOR BIORA THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Biora Therapeutics, Inc.

Actions

BIOR

US74319F3055

Temps réel estimé Cboe BZX
Autres places de cotation
 16:23:58 16/07/2024 		Varia. 5j. Varia. 1 janv.
0,723 USD +1,36 % Graphique intraday de Biora Therapeutics, Inc. +10,59 % -45,93 %
09/07 Athyrium Capital Management engage des discussions avec Biora Therapeutics Inc. CI
01/07 Biora Therapeutics, Inc. annonce les résultats positifs de son essai clinique sur le BT-600 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Biora Therapeutics to Host Virtual KOL Event on NaviCap Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics : Corporate Presentation July 2024
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600
Biora Therapeutics : Next Gen Peptide Formulation & Delivery Summit Presentation June 2024
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
Biora Therapeutics Provides Information to the Shareholders
Biora Therapeutics, Inc. Appoints Jeffrey A. Ferrell as Director
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap Platform at Digestive Disease Week 2024
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
Biora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Earnings Flash (BIOR) BIORA THERAPEUTICS Reports Q1 Revenue $542,000
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600
Biora Therapeutics : Form 8937 – Convertible Note Exchange (December 19, 2023)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BIOR
  4. Actualités Biora Therapeutics, Inc.
  5. Autres langues